These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 21091110)

  • 1. Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation.
    Weissenbacher A; Boesmueller C; Brandacher G; Oellinger R; Pratschke J; Schneeberger S
    Immunotherapy; 2010 Nov; 2(6):783-90. PubMed ID: 21091110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
    Agarwal A; Shen LY; Kirk AD
    Transpl Immunol; 2008 Nov; 20(1-2):6-11. PubMed ID: 18824230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation.
    Magliocca JF; Knechtle SJ
    Transpl Int; 2006 Sep; 19(9):705-14. PubMed ID: 16918530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of alemtuzumab in organ transplantation: current clinical status.
    Ciancio G; Burke GW; Warque ME; Miller J
    BioDrugs; 2006; 20(2):85-92. PubMed ID: 16626166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
    Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
    Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab (Campath-1H): a systematic review in organ transplantation.
    Morris PJ; Russell NK
    Transplantation; 2006 May; 81(10):1361-7. PubMed ID: 16732169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab.
    Weaver TA; Kirk AD
    Transplantation; 2007 Dec; 84(12):1545-7. PubMed ID: 18165760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humanized Monoclonal Antibody Alemtuzumab Treatment in Transplant.
    Bhowmick M; Auckbarallee F; Edgar P; Ray A; Dasgupta S
    Exp Clin Transplant; 2016 Feb; 14(1):17-21. PubMed ID: 26862819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.
    Gómez-Almaguer D; Ruiz-Argüelles GJ; del Carmen Tarín-Arzaga L; González-Llano O; Gutiérrez-Aguirre H; Cantú-Rodríguez O; Jaime-Pérez J; Carrasco-Yalán A; Giralt S
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):10-5. PubMed ID: 18158956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Some observations on prope tolerance.
    Calne R; Watson CJ
    Curr Opin Organ Transplant; 2011 Aug; 16(4):353-8. PubMed ID: 21666472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use.
    Das B; Shoemaker L; Recto M; Austin E; Dowling R
    J Heart Lung Transplant; 2008 Feb; 27(2):242-4. PubMed ID: 18267235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
    Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
    Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
    Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.
    Kirsch BM; Haidinger M; Zeyda M; Böhmig GA; Tombinsky J; Mühlbacher F; Watschinger B; Hörl WH; Säemann MD
    Transpl Immunol; 2006 Nov; 16(3-4):254-7. PubMed ID: 17138063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab.
    Ravandi F; O'Brien S
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):39-51. PubMed ID: 15757437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
    Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients.
    Knechtle SJ
    Pediatr Transplant; 2004 Apr; 8(2):106-12. PubMed ID: 15049789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monocyte-mediated acute renal rejection after combined treatment with preoperative Campath-1H (alemtuzumab) and postoperative immunosuppression.
    Zhang PL; Malek SK; Prichard JW; Lin F; Yahya TM; Schwartzman MS; Latsha RP; Skaletsky M; Norfolk ER; Brown RE; Hartle JE; Potdar S
    Ann Clin Lab Sci; 2004; 34(2):209-13. PubMed ID: 15228236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
    Tibes R; Keating MJ; Ferrajoli A; Wierda W; Ravandi F; Garcia-Manero G; O'Brien S; Cortes J; Verstovsek S; Browning ML; Faderl S
    Cancer; 2006 Jun; 106(12):2645-51. PubMed ID: 16688777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.